Two Sigma Investments’s Aprea Therapeutics APRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-842
Closed -$11K 2788
2022
Q3
$11K Sell
842
-2,177
-72% -$38.6K ﹤0.01% 2412
2022
Q2
$45K Buy
3,019
+2,088
+224% +$48.1K ﹤0.01% 2355
2022
Q1
$35K Buy
+931
New +$38.2K ﹤0.01% 2509
2021
Q2
Sell
-16,168
Closed -$1.65M 4020
2021
Q1
$1.65M Buy
16,168
+8,227
+104% +$960K ﹤0.01% 1864
2020
Q4
$781K Buy
+7,941
New +$3.78M ﹤0.01% 2191

Other funds holding APRE

Two Sigma Investments's APRE Position: Q4 2022 in Review

Two Sigma Investments sold out of Aprea Therapeutics (APRE) in Q4 2022, closing a stake of 842 shares — an estimated $11K sold.

Two Sigma Investments first reported a position in APRE in Q4 2020 and held it in 5 quarters. The position peaked at $1.65M in Q1 2021. 24 funds tracked by Wall St. Rank hold APRE as of Q4 2022.

  • Two Sigma Investments reported no remaining Aprea Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Investments sold 842 Aprea Therapeutics shares in Q4 2022, an estimated $11K.
  • Two Sigma Investments first reported a position in Aprea Therapeutics in Q4 2020 and held it in 5 quarters.
  • Two Sigma Investments's Aprea Therapeutics position peaked at $1.65M in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.